Kulohoma Benard W, Gray Katherine, Kamng'ona Arox, Cornick Jennifer, Bentley Stephen D, Heyderman Robert S, Everett Dean B
The Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Clin Vaccine Immunol. 2013 Nov;20(11):1729-35. doi: 10.1128/CVI.00403-13. Epub 2013 Sep 11.
The pneumococcal pilus has been shown to be an important determinant of adhesion and virulence in mouse models of colonization, pneumonia, and bacteremia. A pilus is capable of inducing protective immunity, supporting its inclusion in next-generation pneumococcal protein vaccine formulations. Whether this vaccine target is common among pneumococci in sub-Saharan Africa is uncertain. To define the prevalence and genetic diversity of type I and II pili among invasive pneumococci in Malawi prior to the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into routine childhood immunization, we examined 188 Streptococcus pneumoniae isolates collected between 2002 and 2008 (17% serotype 1). In this region of high disease burden, we found a low frequency of invasive piliated pneumococci (14%) and pilus gene sequence diversity similar to that seen previously in multiple global pneumococcal lineages. All common serotypes with pilus were covered by PCV13 and so we predict that pilus prevalence will be reduced in the Malawian pneumococcal population after PCV13 introduction.
在定植、肺炎和菌血症小鼠模型中,肺炎球菌菌毛已被证明是粘附和毒力的重要决定因素。菌毛能够诱导保护性免疫,这支持将其纳入下一代肺炎球菌蛋白疫苗配方。这种疫苗靶点在撒哈拉以南非洲的肺炎球菌中是否常见尚不确定。为了在13价肺炎球菌结合疫苗(PCV13)引入儿童常规免疫之前,确定马拉维侵袭性肺炎球菌中I型和II型菌毛的流行率和遗传多样性,我们检查了2002年至2008年间收集的188株肺炎链球菌分离株(17%为1型血清型)。在这个疾病负担高的地区,我们发现侵袭性菌毛肺炎球菌的频率较低(14%),菌毛基因序列多样性与之前在多个全球肺炎球菌谱系中观察到的相似。所有带有菌毛的常见血清型都被PCV13覆盖,因此我们预测,引入PCV13后,马拉维肺炎球菌群体中菌毛的流行率将会降低。